Acura Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACUR research report →
Companywww.acurapharm.com
Acura Pharmaceuticals, Inc. , an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.
- CEO
- Robert Jones
- IPO
- 1986
- Employees
- 9
- HQ
- Palatine, IL, US
Price Chart
Valuation
- Market Cap
- $13.20K
- P/E
- -0.01
- P/S
- 0.01
- P/B
- 0.05
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.24%
- Op Margin
- -77.67%
- Net Margin
- -56.24%
- ROE
- 30.77%
- ROIC
- -295.38%
Growth & Income
- Revenue
- $1.56M · -56.22%
- Net Income
- $-879,000 · 27.24%
- EPS
- $-0.02 · 50.00%
- Op Income
- $-1,214,000
- FCF YoY
- -3.20%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -54.49
- Avg Volume
- 1.02K
Get TickerSpark's AI analysis on ACUR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 25 | THANGARAJ IMMANUEL | other | 50,000 |
Our ACUR Coverage
We haven't published any research on ACUR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACUR Report →